Evolus, Inc. (EOLS)
NASDAQ: EOLS · IEX Real-Time Price · USD
11.96
+0.23 (1.96%)
At close: Jul 19, 2024, 4:00 PM
12.02
+0.06 (0.50%)
Pre-market: Jul 20, 2024, 9:28 AM EDT
Evolus Revenue
Evolus had revenue of $219.70M in the twelve months ending March 31, 2024, with 40.45% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $59.33M with 42.21% year-over-year growth. In the year 2023, Evolus had annual revenue of $202.09M with 35.98% growth.
Revenue (ttm)
$219.70M
Revenue Growth
+40.45%
P/S Ratio
3.41
Revenue / Employee
$804,751
Employees
273
Market Cap
748.82M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 202.09M | 53.47M | 35.98% |
Dec 31, 2022 | 148.62M | 48.94M | 49.10% |
Dec 31, 2021 | 99.67M | 43.13M | 76.29% |
Dec 31, 2020 | 56.54M | 21.62M | 61.89% |
Dec 31, 2019 | 34.93M | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Embecta | 1.13B |
Phibro Animal Health | 999.56M |
Travere Therapeutics | 183.23M |
OrthoPediatrics | 161.83M |
Sage Therapeutics | 91.06M |
4D Molecular Therapeutics | 20.45M |
Dianthus Therapeutics | 2.26M |
Pliant Therapeutics | 248.00K |
EOLS News
- 4 days ago - Evolus to Report Second Quarter Financial Results on July 31, 2024 - Business Wire
- 20 days ago - Evolus Announces Appointment of Albert G. White III to Board of Directors - Business Wire
- 27 days ago - Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products - Business Wire
- 5 weeks ago - Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain - Business Wire
- 6 weeks ago - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting - Business Wire
- 2 months ago - Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women's Wear Daily Beauty CEO Summit - Business Wire
- 2 months ago - Evolus' Sandra Beaver Named Orange County Business Journal's Public Company CFO of the Year - Business Wire